Drug Profile

Pertuzumab biosimilar - Biocon Biologics

Alternative Names: PERT-IJS

Latest Information Update: 22 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator
Developer Biocon Biologic
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; Dimerisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical HER2 positive breast cancer

Most Recent Events

21 Sep 2023 Preclinical trials in HER2-positive-breast-cancer in India (IV)
12 Sep 2023 Biocon Biologics plans a phase III trial for HER2 positive breast cancer (Combination therapy, Late-stage disease, Neoadjuvant therapy) in December 2023 (IV) (NCT06038539)
29 Nov 2022 Biocon acquires the global biosimilars business of Viatris

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com